Gout is often framed as an episodic condition. A flare erupts, pain escalates, treatment is adjusted, and once symptoms subside, attention shifts away from the disease.
This framing overlooks how gout frequently behaves over time. In some individuals, symptoms don’t fully resolve between flares. Joint discomfort lingers, movement becomes less predictable during everyday activities, and recovery is incomplete. This pattern is commonly described as chronic gout and is often under-recognised because it doesn’t always present with severe or disabling pain.
Not everyone with gout will develop chronic disease. However, as diagnoses occur earlier and life expectancy increases, management decisions increasingly shape joint function over decades rather than months. What happens between flares is therefore central to how gout should be assessed and managed.
When “no flares” does not mean inactive disease
Gout control is often judged by flare frequency. If severe attacks are infrequent or absent, the condition is assumed to be stable.
That assumption can be misleading. Even without acute flares, urate crystal deposition and ongoing joint inflammation may persist. Over time, this can affect joint structure, range of motion, and stability. Pain may be limited, but joint function can continue to change.
Clinical practice distinguishes between disease that appears stable and disease that’s truly clinically inactive. Blood tests may fall within recommended ranges and medication may be taken consistently, while joints fail to return fully to baseline between episodes. In such cases, disease impact may only become apparent once function declines.
According to Dr Sollano, a board-certified rheumatologist, infrequent gout flare-ups don’t always reflect the full activity of the disease. While having two or fewer flares a year is generally considered a sign that gout is clinically under control, this assessment needs to be considered alongside serum uric acid levels, which play a key role in long-term disease management.
Gout is a chronic condition and may require long-term treatment. Even when flare-ups are infrequent, persistently elevated uric acid levels can increase the risk of developing flares leading to irreversible joint damage over time. In theory, maintaining a serum uric acid level of 6 mg/dL or below is ideal to help prevent flare-ups and reduce the risk of long-term complications.
Regular follow-up therefore remains important. Without routine check-ups and laboratory tests, care may not be fully optimised, regardless of how often flare-ups occur. Patients also present with gout differently and perceive pain differently. In clinical practice, there are patients who report few or no flare-ups but are found on consultation to have tophaceous gout, where uric acid crystals have formed visible lumps under the skin, indicating ongoing disease activity.
For this reason, a thorough medical history and careful physical examination are essential. Clinicians should actively look for tophi, which commonly appear in the toes, ankles, knees, elbows, and fingers, and can sometimes be found in less obvious areas such as the ears.
Identifying these signs early helps detect ongoing disease and guides appropriate management, even when symptoms appear infrequent.
How gout commonly presents between flares
Between flares, gout often doesn’t feel like an illness. There may be no swelling or sharp pain. Instead, the body functions differently from how it used to.
Certain joints may feel less dependable. A toe can feel stiff when pushing off while walking. An ankle may feel less steady on stairs. Knees may tolerate routine movement but become uncomfortable prolonged standing or walking.
Common experiences include:
- persistent stiffness without visible swelling
- slower or more restricted movement
- morning stiffness that takes longer to resolve
- increased caution on stairs or uneven ground
- intermittent discomfort without a clear trigger
Because these changes fluctuate, they’re easy to dismiss and are often attributed to age, footwear, or daily fatigue. Over time, small adjustments become routine: routes are chosen to reduce strain, footwear is selected for comfort rather than preference, and activities that stress certain joints are shortened or avoided.
These adaptations ease discomfort, but when they become habitual, they signal a change in joint function that warrants reassessment.
Diet-related changes can sometimes be accompanied by a degree of dehydration, which may alter uric acid balance and increase the likelihood of a gout flare. For this reason, dietary changes should be approached gradually and intentionally, with close attention to adequate hydration.
Besides diet alone, factors such as stress and interactions with other medications (i.e. maintenance anti-hypertensive medications) are increasingly recognised as playing a meaningful role in gout management. Dr Sollano notes that these influences may help explain why some patients continue to experience flares despite adhering to dietary advice.
These considerations should be discussed openly with patients, alongside the importance of medication adherence and regular follow-up. Addressing hydration, stress, and potential medication interactions as part of routine care can help optimise long-term gout control, rather than focusing on diet in isolation.
When people delay seeking care
Chronic gout often develops without severe pain, which contributes to delayed review. Symptoms fluctuate: some days feel manageable, while others interfere with daily routines without creating urgency.
This uncertainty leads many people to wait, particularly when flares are infrequent or blood tests appear acceptable. Over time, adjustment replaces review, and reassessment is delayed until changes become harder to ignore.
What doctors need to hear about gout between flares
One of the most common challenges in chronic gout care is communication. People often describe themselves as “managing”, even when joint function has changed.
Clinical assessment is more effective when symptoms are described in terms of function, pattern, and change over time, rather than pain alone.
Clinically useful descriptions include:
These details help determine whether gout is truly inactive or whether ongoing joint involvement persists despite fewer acute attacks. Blood tests alone don’t capture this context.
Why prescriptions alone do not define control
Taken together, these patterns expose a limitation in how gout control is commonly defined.
Medication remains central to management, but prescriptions alone don’t reflect how gout behaves over years of disease. Long-term assessment depends on how joints function between flares and whether mobility or daily activity is gradually narrowing.
A reduction in flare frequency matters, but it isn’t the sole marker of stability. When symptom-free periods still involve stiffness or limitation, gout may be controlled on paper but active in practice. Recognising functional change earlier allows management to shift before joint limitation becomes established.
Gout flare-ups can still occur even when serum uric acid levels are maintained within the recommended range, which can be confusing for both patients and clinicians. This is because flare-ups are influenced by multiple factors, not uric acid levels alone.
During an acute flare, patients may present with serum uric acid levels that are within the normal range or even below the saturation point of 6.8 mg/dL, which can obscure the clinical picture. Current clinical guidelines recommend maintaining serum uric acid levels at 6.0 mg/dL for gout patients, and 5.0 mg/dL for patients with tophi, regardless of the reference ranges reported by individual laboratories. These targets have been shown to be effective in controlling gout and reducing flare frequency over time.
Even when uric acid levels are within these targets, certain stressors may still trigger flare-ups. These include infections, surgery, myocardial infarction, as well as binge eating or consumption of foods high in purines, and excessive alcohol intake. Such events can provoke inflammation despite otherwise stable biochemical control.
Medication adherence also plays a significant role. Patients may not always take medications exactly as prescribed, which can affect disease control. Open discussions about medication use allow clinicians to determine whether treatment adjustments are needed, whether in dosage or frequency, and whether further patient education may help improve outcomes.
Gout as part of a broader metabolic picture
For many people, chronic gout reflects wider metabolic strain rather than isolated joint disease. Elevated urate levels often coexist with insulin resistance, dyslipidaemia, hypertension, and changes in kidney handling of uric acid.
When gout persists between flares, it may signal not only ongoing joint involvement but also broader metabolic imbalance that influences how the disease behaves over time. Improving metabolic health doesn’t replace gout treatment, but it can influence urate handling, inflammatory tone, and flare patterns.
When primary care may no longer be enough
Many people are managed effectively in primary care, particularly earlier in the disease course. Ongoing review by a general practitioner remains appropriate for many.
Specialist input, most commonly from a rheumatologist, becomes relevant for assessment of long-term disease behaviour when the pattern of gout changes. Referral reflects evolving disease behaviour rather than poor management or treatment failure.
At this stage, reassessment isn’t simply about changing medication. It clarifies whether symptoms reflect ongoing disease activity, cumulative joint change, or additional contributing factors, and it allows goals to be reset toward long-term joint function and mobility.
Referral to a rheumatologist is often considered when:
Reframing the goal of long-term gout care
The goal of gout management extends beyond reducing flares. It’s preserving joint integrity, maintaining mobility, and sustaining confidence in movement over time.
Gradual functional change is a valid reason to revisit management, even without severe pain, reflecting the cumulative nature of gout and the need for ongoing assessment.
Gout is closely linked to kidney health and other metabolic conditions, which is why current clinical guidelines recommend routine monitoring for associated co-morbidities. As part of this approach, renal function monitoring is both standard and necessary in the long-term management of gout.
Regular assessment of kidney function provides important information for optimising treatment. It helps clinicians adjust medications such as colchicine and non-steroidal anti-inflammatory drugs (NSAIDs) appropriately for patients with varying levels of kidney impairment, ensuring treatment remains both effective and safe.
Some guidelines also reflect a more proactive stance on preventing kidney damage. For example, Japanese gout guidelines recommend initiating urate-lowering therapy when serum uric acid levels reach 9 mg/dL or higher, even in patients without symptoms. This approach acknowledges the established link between sustained hyperuricaemia and progressive kidney damage, and highlights the importance of early intervention rather than waiting for clinical complications to emerge.
Looking ahead: when standard approaches fall short
For a subset of people, gout remains difficult to control despite standard care. This has prompted growing interest in more individualised approaches that account for variation in disease behaviour and treatment response.
Living in an era where modern medicine is advancing rapidly has opened up a growing range of possibilities for gout management, including for patients who don’t respond well to standard treatments. Dr Sollano notes that while evidence for precision medicine approaches in treatment-resistant gout is still evolving, several avenues are currently being studied.
These include the potential use of anti-TNF therapies such as etanercept and infliximab, anti-IL-6 therapy like tocilizumab, as well as approaches that target autophagy (for example, rapamycin) and inflammasome pathways. Research has also explored the use of SGLT2 inhibitors, such as dapagliflozin, as adjuncts to urate-lowering therapy. With the dawn of peptide receptor agonists (i.e. semaglutide and tirzepatide) and its effects on weight loss and subsequently lowering uric acid, there are genuinely many exciting new treatment strategies to look forward to.
At the same time, it’s important to recognise that existing treatments may not always be fully utilised. Medications such as uricosurics and pegloticase can be effective in selected patients, but their use remains limited in some parts of the world due to issues of availability and cost. Addressing these gaps is likely to be just as important as developing new therapies when it comes to improving outcomes for patients with difficult-to-treat gout.
When to reassess gout, even without flares
Gout doesn’t become chronic overnight. Progression usually occurs when subtle changes between flares are normalised or overlooked.
Earlier management recognises change before function is lost, rather than reacting once limitations are established. Persistent stiffness, reduced range of motion, or increasing reliance on workarounds are signals that deserve reassessment.
Reassessment remains appropriate even when flares are infrequent and blood tests appear acceptable. It allows care to shift from reacting to attacks to protecting long-term joint health.
A simple question is revisit periodically is:
If the answer is no, that alone is reason enough to seek review. Earlier reassessment reflects how gout evolves and offers the best opportunity to limit long-term joint impact.
Dr Ma. Hanna Monica Z Sollano
Section Chief of Rheumatology
Cardinal Santos Medical Center, Philippines
Instagram: @cardinalsantos
This article was produced by Healthful For You. The views and opinions expressed throughout are those of the authors and do not necessarily reflect those of the Expert Contributor. The Expert Contributor has provided input solely for the EXPERT INSIGHT and TIP segments, based on their professional expertise. These comments are intended to offer general guidance and may not apply to all individuals. Any interpretations or conclusions beyond that section are those of Healthful For You. This article is not a substitute for personalised medical advice, diagnosis, or treatment. Please consult your doctor or a healthcare professional regarding your specific health needs.
We hope you found this article informative. Healthful For You welcomes contributions from healthcare professionals, patients, and community members. If you have a story, research, or a perspective that can enrich our dialogue, please get in touch with us at [email protected].